** Shares of Maze Therapeutics MAZE.O rise 4.8% to $11.34

** Wall Street brokerages start coverage of the drug developer on a bullish note as IPO research quiet period ends

** J.P. Morgan starts coverage with "overweight" rating and $30 PT, a 177.2% upside to the stock's last close

** "With data for MZE829 available, we see its potential in addressing a wide population, competitive pricing, market share, and high success probability as key factors for boosting MAZE shares" - J.P. Morgan analysts referring to co's kidney disease therapy candidate

** Leerink Partners starts coverage with "outperform" rating and PT of $28, a 158.8% upside to the stock's last close

** "Chronic kidney disease represents a significant market opportunity, especially considering the major drain on overall Medicare spending. We assume gross peak sales of ~$1.8B in CKD" - Leerink Partners

** J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities were the underwriters for the IPO

** Stock has fallen 32% since its Nasdaq debut in January

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))